190 related articles for article (PubMed ID: 30659170)
1. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.
Sano M; Ijichi H; Takahashi R; Miyabayashi K; Fujiwara H; Yamada T; Kato H; Nakatsuka T; Tanaka Y; Tateishi K; Morishita Y; Moses HL; Isayama H; Koike K
Oncogenesis; 2019 Jan; 8(2):8. PubMed ID: 30659170
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
3. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases.
Cheng Y; Ma XL; Wei YQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):289-312. PubMed ID: 30703432
[TBL] [Abstract][Full Text] [Related]
4. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
5. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
6. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
7. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
Dai Z; Lin X; Wang X; Zou X; Yan Y; Wang R; Chen Y; Tasiheng Y; Ma M; Wang X; Cheng H; Yu X; Liu C
Cancer Immunol Immunother; 2024 Mar; 73(4):61. PubMed ID: 38430267
[TBL] [Abstract][Full Text] [Related]
8. Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis.
Purohit A; Saxena S; Varney M; Prajapati DR; Kozel JA; Lazenby A; Singh RK
Am J Pathol; 2021 Apr; 191(4):759-771. PubMed ID: 33453178
[TBL] [Abstract][Full Text] [Related]
9. Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism.
Sano M; Takahashi R; Ijichi H; Ishigaki K; Yamada T; Miyabayashi K; Kimura G; Mizuno S; Kato H; Fujiwara H; Nakatsuka T; Tanaka Y; Kim J; Masugi Y; Morishita Y; Tanaka M; Ushiku T; Nakai Y; Tateishi K; Ishii Y; Isayama H; Moses HL; Koike K
Gut; 2021 Sep; 70(9):1713-1723. PubMed ID: 33087490
[TBL] [Abstract][Full Text] [Related]
10. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
11. CD13
Zhang J; Xu X; Shi M; Chen Y; Yu D; Zhao C; Gu Y; Yang B; Guo S; Ding G; Jin G; Wu CL; Zhu M
Oncoimmunology; 2017; 6(2):e1258504. PubMed ID: 28344866
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
13. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer.
Ji HZ; Liu B; Ren M; Li S; Zheng JF; Liu TY; Yu HH; Sun Y
Expert Rev Clin Immunol; 2024 May; 20(5):559-569. PubMed ID: 38224014
[TBL] [Abstract][Full Text] [Related]
14. Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis.
Zhang F; Mulvaney O; Salcedo E; Manna S; Zhu JZ; Wang T; Ahn C; Pop LM; Hannan R
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067390
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer.
Ijichi H
Oncoimmunology; 2012 Jul; 1(4):569-571. PubMed ID: 22754790
[TBL] [Abstract][Full Text] [Related]
16. DIF-1 exhibits anticancer activity in breast cancer via inhibition of CXCLs/CXCR2 axis-mediated communication between cancer-associated fibroblasts and cancer cells.
Seto-Tetsuo F; Arioka M; Miura K; Inoue T; Igawa K; Tomooka K; Sasaguri T
Int Immunopharmacol; 2023 Apr; 117():109913. PubMed ID: 36812674
[TBL] [Abstract][Full Text] [Related]
17. Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis.
Wu X; Xia J; Wang Z; Xu Z; Liu K; Fu X; Deng H
J Ethnopharmacol; 2022 Sep; 295():115277. PubMed ID: 35427725
[TBL] [Abstract][Full Text] [Related]
18. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential.
Cannon A; Thompson C; Hall BR; Jain M; Kumar S; Batra SK
Genes Cancer; 2018 Mar; 9(3-4):78-86. PubMed ID: 30108679
[TBL] [Abstract][Full Text] [Related]
19. Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma.
Tian Z; Hou X; Liu W; Shao C; Gao L; Jiang J; Zhang L; Han Z; Wei L
Cancer Cell Int; 2022 Nov; 22(1):362. PubMed ID: 36403057
[TBL] [Abstract][Full Text] [Related]
20. Zeb1 in Stromal Myofibroblasts Promotes
Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
